CPBTD
SRPT icon

Central Pacific Bank - Trust Division’s Sarepta Therapeutics SRPT Stock Holding History

Central Pacific Bank - Trust Division’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-698
Closed -$110K – 941
2024
Q2 		$110K Sell
698
-2,530
-78% -$325K 0.01% 650
2024
Q1 		$414K Buy
+3,228
New +$395K 0.05% 382

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Central Pacific Bank - Trust Division's SRPT Position: Q3 2024 in Review

Central Pacific Bank - Trust Division sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 698 shares — an estimated $110K sold.

Central Pacific Bank - Trust Division first reported a position in SRPT in Q1 2024 and held it in 2 quarters. The position peaked at $414K in Q1 2024. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Central Pacific Bank - Trust Division reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Central Pacific Bank - Trust Division sold 698 Sarepta Therapeutics shares in Q3 2024, an estimated $110K.
  • Central Pacific Bank - Trust Division first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 2 quarters.
  • Central Pacific Bank - Trust Division's Sarepta Therapeutics position peaked at $414K in Q1 2024.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Central Pacific Bank - Trust Division's 13F filing for Q3 2024, filed 2 Oct 2024.